Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: MCN011
MIFTS: 36

Mucinoses

Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Mucinoses

About this section

MalaCards integrated aliases for Mucinoses:

Name: Mucinoses 12 44 15 73

External Ids:

Disease Ontology 12 DOID:3141
MeSH 44 D017520
SNOMED-CT 68 11528001
UMLS 73 C0162855
Sources

Summaries for Mucinoses

About this section
MalaCards based summary : Mucinoses is related to spinal cord astrocytoma and hand, foot and mouth disease. An important gene associated with Mucinoses is CHST11 (Carbohydrate Sulfotransferase 11), and among its related pathways/superpathways are Allograft rejection and Interferon gamma signaling. The drugs Polidocanol and Ranibizumab have been mentioned in the context of this disorder. Affiliated tissues include eye, bone and bone marrow, and related phenotypes are hematopoietic system and endocrine/exocrine gland

Sources

Related Diseases for Mucinoses

About this section

Diseases related to Mucinoses via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 14)
# Related Disease Score Top Affiliating Genes
1 spinal cord astrocytoma 10.2 CD44 IFNB1
2 hand, foot and mouth disease 10.1 C4A IFNG
3 chronic inflammatory demyelinating polyradiculoneuropathy 10.1 IFNB1 IFNG
4 cerebral primitive neuroectodermal tumor 10.1 CD44 IFNB1
5 breast giant fibroadenoma 10.1 CD44 IFNG
6 hypothyroidism 9.9
7 connective tissue disease 9.9
8 chilblain lupus 1 9.9 CXCL9 IFNB1
9 severe acute respiratory syndrome 9.7 IFNB1 IFNG
10 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.6 IFNG INS
11 scleredema adultorum 9.5 CXCL9 FBN1 INS
12 craniopharyngioma 9.4 INS KRT14
13 nervous system disease 9.4 IFNB1 IFNG INS
14 diabetes mellitus, insulin-dependent 9.3 C4A IFNG INS

Graphical network of the top 20 diseases related to Mucinoses:



Diseases related to Mucinoses
Sources

Symptoms & Phenotypes for Mucinoses

About this section

MGI Mouse Phenotypes related to Mucinoses:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.95 CD44 CHST11 FBN1 IFNB1 IFNG INS
2 endocrine/exocrine gland MP:0005379 9.91 CD44 CHST11 FBN1 IFNG INS KRT14
3 immune system MP:0005387 9.91 INS KRT14 CD44 CHST11 FBN1 IFNB1
4 digestive/alimentary MP:0005381 9.85 CD44 CHST11 IFNG INS KRT14
5 muscle MP:0005369 9.72 CD44 CHST11 FBN1 IFNG INS
6 renal/urinary system MP:0005367 9.65 CD44 CHST11 FBN1 IFNG INS
7 respiratory system MP:0005388 9.55 CD44 CHST11 FBN1 IFNG KRT14
8 skeleton MP:0005390 9.43 CD44 CHST11 FBN1 IFNB1 IFNG INS
9 vision/eye MP:0005391 9.02 CD44 CHST11 IFNG INS KRT14
Sources

Drugs & Therapeutics for Mucinoses

About this section

Drugs for Mucinoses (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 152)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Polidocanol Approved Phase 4 9002-92-0
2
Ranibizumab Approved Phase 4 347396-82-1 459903
3
Ropivacaine Approved Phase 4,Phase 3,Not Applicable 84057-95-4 71273 175805
4
Ibuprofen Approved Phase 4,Phase 2 15687-27-1 3672
5
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
6
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
7
Hydrocodone Approved, Illicit Phase 4 125-29-1 5284569
8
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 2 76-42-6 5284603
9
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
10
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
11
Nicotinamide Approved, Investigational, Nutraceutical Phase 4 98-92-0 936
12
Tocopherol Approved, Investigational, Nutraceutical Phase 4,Phase 2 1406-66-2 14986
13
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 59-02-9 14985
14 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Angiogenesis Inhibitors Phase 4
16 Angiogenesis Modulating Agents Phase 4
17 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Anesthetics, Local Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Antiemetics Phase 4
22 Antimetabolites Phase 4,Phase 1,Phase 2
23 Antioxidants Phase 4
24 Autonomic Agents Phase 4
25 Gastrointestinal Agents Phase 4
26 Hypolipidemic Agents Phase 4
27 Lipid Regulating Agents Phase 4
28 Micronutrients Phase 4
29 Nicotinic Acids Phase 4
30 Protective Agents Phase 4,Phase 1,Phase 2
31 Tocopherols Phase 4,Phase 2
32 Tocotrienols Phase 4,Phase 2
33 Trace Elements Phase 4
34 Vasodilator Agents Phase 4
35 Vitamin B Complex Phase 4
36 Vitamins Phase 4,Phase 2
37 Antibodies Phase 4,Phase 1,Phase 2
38 Immunoglobulins Phase 4,Phase 1,Phase 2
39 Analgesics Phase 4,Phase 2,Not Applicable
40 Anti-Inflammatory Agents Phase 4,Phase 1,Phase 2
41 Antirheumatic Agents Phase 4,Phase 1,Phase 2
42 Acetaminophen, hydrocodone drug combination Phase 4
43 Analgesics, Non-Narcotic Phase 4,Phase 2
44 Analgesics, Opioid Phase 4,Phase 2
45 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2
46 Antipyretics Phase 4,Phase 2
47 Antitussive Agents Phase 4
48 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
49 Cyclooxygenase Inhibitors Phase 4,Phase 2
50 Narcotics Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 196)
# Name Status NCT ID Phase Drugs
1 An Assessment of Intra-lesional 3% Polidocanol Solution in the Treatment of Digital Myxoid Cyst Unknown status NCT02154789 Phase 4 polidocanol
2 Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema Unknown status NCT02055911 Phase 4 Ranibizumab
3 Sleep Quality After Stellate-ganglion Block of Patients Undergoing Breast Cancer Operation Completed NCT02651519 Phase 4 0.25% ropivacaine hydrochloride;saline
4 Effect of Stellate Ganglion Block on Meniere's Disease Completed NCT01574313 Phase 4 0.25mg, fludiazine;25mg cephadol@ (diphenidol);200mg kentons@ (tocopherol nicotinate).
5 Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy Completed NCT00607386 Phase 4
6 A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI Completed NCT00299000 Phase 4 Naglazyme
7 A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease Completed NCT00144781 Phase 4
8 A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients Completed NCT00144768 Phase 4 laronidase
9 A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants Recruiting NCT00418821 Phase 4
10 Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age Active, not recruiting NCT02455622 Phase 4 Elaprase for intravenous (IV) infusion
11 Post-operative Analgesia in Elective, Soft-tissue Hand Surgery Enrolling by invitation NCT02029235 Phase 4 Acetaminophen/Hydrocodone;Acetaminophen/Ibuprofen
12 Morquio's Syndrome: a Case Study Terminated NCT00609440 Phase 4
13 BMN 110 Phase 3B in Australian Patients Unknown status NCT01966029 Phase 3 BMN 110
14 Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis Unknown status NCT01238328 Phase 2, Phase 3 Conditioning regimen;Graft-versus-host disease (GVHD) prophylaxis
15 Surgery Versus Manual Rupture for Dorsal Carpal Ganglion Completed NCT01017900 Phase 3
16 A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7) Completed NCT02230566 Phase 3 UX003
17 Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment Completed NCT02055118 Phase 2, Phase 3
18 A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) Completed NCT01275066 Phase 3 BMN 110 Weekly;Placebo;BMN 110 Every Other Week
19 Safety and Efficacy of Hunterase Completed NCT01645189 Phase 3
20 Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) Completed NCT01415427 Phase 3 BMN 110 - Weekly;BMN 110 - Every Other Week
21 Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I Completed NCT00912925 Phase 3
22 Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase Completed NCT00630747 Phase 2, Phase 3
23 Study of rhASB in Patients With Mucopolysaccharidosis VI Completed NCT00104234 Phase 3 N-acetylgalactosamine 4-sulfatase;Placebo/rhASB
24 Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II) Completed NCT00069641 Phase 2, Phase 3
25 Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI Completed NCT00067470 Phase 3 Placebo;N-acetylgalactosamine 4-sulfatase
26 Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease Completed NCT00258011 Phase 3
27 Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients Completed NCT00146770 Phase 3
28 Infiltration in the Region of the Palatine Ganglion Spheno by Ropivacaine on Postoperative Pain Recruiting NCT02821169 Phase 3 ropivacaine;saline solution 0.9%
29 A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7 Active, not recruiting NCT02432144 Phase 3 UX003
30 Long-Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Patients With Hunter Syndrome That Have Completed Study HGT-HIT-094 Enrolling by invitation NCT02412787 Phase 2, Phase 3 Idursulfase-IT
31 A Study of JR-141 in Patients With Mucopolysaccharidosis II Not yet recruiting NCT03568175 Phase 2, Phase 3 JR-141
32 ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases Terminated NCT00654433 Phase 3
33 Clinical Trial of Growth Hormone in MPS I, II, and VI Terminated NCT00748969 Phase 2, Phase 3 Somatropin (DNA origin)
34 Does Stellate Ganglion Block Decrease Stress Response of Intubation? Unknown status NCT02732093 Phase 2 Na.Cl 0.9% (placebo);lidocaine 2%
35 The Efficacy of Stellate Ganglion Block as Post-traumatic Stress Disorder (PTSD) Therapy: A Pilot Study Unknown status NCT01533610 Phase 2
36 Analgesic Effect of an Injection of Botulinum Toxin Type A in the Ganglion Impar in Patients With Chronic Proctalgia Completed NCT01331356 Phase 2 Botox
37 A Study of JR-141 in Patients With Mucopolysaccharidosis Type II Completed NCT03128593 Phase 1, Phase 2 JR-141
38 Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI Completed NCT02437253 Phase 1, Phase 2 Adalimumab
39 Long-term Follow-up of Sanfilippo Type A Patients Treated by Intracerebral SAF-301 Gene Therapy Completed NCT02053064 Phase 1, Phase 2
40 An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of Study Drug UX003 Recombinant Human Beta-glucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7) Completed NCT01856218 Phase 1, Phase 2 UX003
41 Intracerebral Gene Therapy for Sanfilippo Type A Syndrome Completed NCT01474343 Phase 1, Phase 2
42 Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease Completed NCT02060526 Phase 2 Recombinant human heparan N-sulfatase [rhHNS]
43 To Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome Patients Completed NCT01301898 Phase 1, Phase 2 GC1111_0.5mg/kg;GC1111_1.0mg/kg;Elaprase_0.5mg/kg
44 Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome) Completed NCT01515956 Phase 2 BMN 110
45 A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA Completed NCT00884949 Phase 1, Phase 2 BMN 110
46 Immune Tolerance Study With Aldurazyme® (Laronidase) Completed NCT00741338 Phase 1, Phase 2 Cyclosporine A (CsA);Azathioprine (Aza)
47 Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders Completed NCT01043640 Phase 2 Campath-1H;Cyclophosphamide;Busulfan;Cyclosporine A;Mycophenolate Mofetil
48 Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an IDDD in MPS IIIA Patients Completed NCT01155778 Phase 1, Phase 2
49 A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase® Completed NCT00920647 Phase 1, Phase 2 Idursulfase IT (1 mg);Idursulfase IT (10 mg);Idursulfase IT (30 mg)
50 Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells Completed NCT00730314 Phase 1, Phase 2

Search NIH Clinical Center for Mucinoses

Cochrane evidence based reviews: mucinoses

Sources

Genetic Tests for Mucinoses

About this section
Sources

Anatomical Context for Mucinoses

About this section

MalaCards organs/tissues related to Mucinoses:

41
Eye, Bone, Bone Marrow, Brain, Trigeminal Ganglion, Dorsal Root Ganglion, Spinal Cord
Sources

Publications for Mucinoses

About this section

Articles related to Mucinoses:

(show all 16)
# Title Authors Year
1
Trauma-induced Focal Nodular Mucinoses: A Rare Entity. ( 29441300 )
2018
2
Review of Primary Cutaneous Mucinoses in Nonlupus Connective Tissue Diseases. ( 28673091 )
2017
3
Diffuse cutaneous mucinoses. ( 12170882 )
2002
4
Cutaneous mucinoses complicating interferon beta-1b therapy. ( 11844903 )
2002
5
Cutaneous mucinoses: microscopic criteria for diagnosis. ( 11391115 )
2001
6
Cutaneous mucinoses and HIV infection. ( 9990377 )
1998
7
The dermal mucinoses. ( 7694631 )
1993
8
Cutaneous toxic mucinoses. ( 1583189 )
1992
9
The new cutaneous mucinoses: a review with an up-to-date classification of cutaneous mucinoses. ( 2007673 )
1991
10
Focal mucinosis in dogs: seven cases and review of cutaneous mucinoses of man and animals. ( 3962080 )
1986
11
The cutaneous mucinoses. ( 2419372 )
1986
12
The acquired cutaneous mucinoses. ( 6486981 )
1984
13
Multiple cutaneous focal mucinoses with hypothyroidism. ( 7053704 )
1982
14
Reticular erythematous mucinosis (REM syndrome) of Steigleder: its relationship to other mucinoses and to chronic erythemata. ( 747554 )
1978
15
The cutaneous mucinoses. ( 4196237 )
1973
16
Histochemical study of acid mucopolysaccharides in mucinoses. ( 13986611 )
1962
Sources

Variations for Mucinoses

About this section
Sources

Expression for Mucinoses

About this section
Search GEO for disease gene expression data for Mucinoses.
Sources

Pathways for Mucinoses

About this section

Pathways related to Mucinoses according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Allograft rejection 1 37
Show member pathways
 12.3 C4A CXCL9 IFNG INS
2
Interferon gamma signaling 66
Show member pathways
 11.99 CD44 IFNB1 IFNG
3
ATF-2 transcription factor network 1
11.11 IFNG INS
4
Senescence and Autophagy in Cancer 1
10.95 CD44 IFNB1 IFNG INS
5
Type II interferon signaling (IFNG) 1
10.7 CXCL9 IFNB1 IFNG
6
Cytokines and Inflammatory Response 1
10.63 IFNB1 IFNG
Sources

GO Terms for Mucinoses

About this section

Cellular components related to Mucinoses according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 C4A CXCL9 FBN1 IFNB1 IFNG INS
2 endoplasmic reticulum lumen GO:0005788 9.33 C4A FBN1 INS
3 extracellular space GO:0005615 9.17 C4A CXCL9 FBN1 IFNB1 IFNG INS

Biological processes related to Mucinoses according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.43 C4A FBN1 INS
2 defense response to virus GO:0051607 9.33 CXCL9 IFNB1 IFNG
3 humoral immune response GO:0006959 9.32 IFNB1 IFNG
4 regulation of signaling receptor activity GO:0010469 9.02 CXCL9 FBN1 IFNB1 IFNG INS
5 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 8.96 IFNB1 IFNG

Molecular functions related to Mucinoses according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.8 CXCL9 IFNB1 IFNG
Sources

Sources for Mucinoses

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....